It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Influenza B viruses (IBVs) cause substantive morbidity and mortality, and yet immunity towards IBVs remains understudied. CD8+ T-cells provide broadly cross-reactive immunity and alleviate disease severity by recognizing conserved epitopes. Despite the IBV burden, only 18 IBV-specific T-cell epitopes restricted by 5 HLAs have been identified currently. A broader array of conserved IBV T-cell epitopes is needed to develop effective cross-reactive T-cell based IBV vaccines. Here we identify 9 highly conserved IBV CD8+ T-cell epitopes restricted to HLA-B*07:02, HLA-B*08:01 and HLA-B*35:01. Memory IBV-specific tetramer+CD8+ T-cells are present within blood and tissues. Frequencies of IBV-specific CD8+ T-cells decline with age, but maintain a central memory phenotype. HLA-B*07:02 and HLA-B*08:01-restricted NP30-38 epitope-specific T-cells have distinct T-cell receptor repertoires. We provide structural basis for the IBV HLA-B*07:02-restricted NS1196-206 (11-mer) and HLA-B*07:02-restricted NP30-38 epitope presentation. Our study increases the number of IBV CD8+ T-cell epitopes, and defines IBV-specific CD8+ T-cells at cellular and molecular levels, across tissues and age.
Influenza B viruses are linked to significant morbidity and mortality, and yet their immunobiology is comparatively poorly understood. Here Menon et al identify influenza B virus-specific CD8+ T cell epitopes and characterise these in adults, children and the elderly.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
2 Monash University, Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
3 University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); CSL Seqirus Ltd, Parkville, Australia (GRID:grid.1008.9)
4 Deepdene Surgery, Deepdene, Australia (GRID:grid.1008.9)
5 Launceston General Hospital, Tasmanian Vaccine Trial Centre, Launceston, Australia (GRID:grid.415834.f) (ISNI:0000 0004 0418 6690); University of Tasmania, School of Health Sciences and School of Medicine, Launceston, Australia (GRID:grid.1009.8) (ISNI:0000 0004 1936 826X); RMIT University, School of Health and Biomedical Science, Melbourne, Australia (GRID:grid.1017.7) (ISNI:0000 0001 2163 3550)
6 Monash University, Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Cardiff University School of Medicine, Institute of Infection and Immunity, Cardiff, UK (GRID:grid.5600.3) (ISNI:0000 0001 0807 5670)
7 University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262)